Reducing preventable maternal mortality remains one of global health's most urgent priorities, with the Maternal Health Market reflecting the technologies, interventions, and healthcare system investments addressing the approximately three hundred thousand annual maternal deaths — ninety-four percent occurring in low and lower-middle-income countries — from largely preventable causes including postpartum hemorrhage, hypertensive disorders, sepsis, and unsafe abortion.

Postpartum hemorrhage — responsible for approximately thirty-five percent of global maternal deaths — can be effectively prevented by active management of the third stage of labor including uterotonics, but the translation of this evidence-based intervention to all deliveries globally has been impeded by drug access, cold chain requirements, and health worker training gaps in high-burden settings. Carbetocin heat-stable formulation — a room-temperature-stable uterotonic requiring no refrigeration — addresses the cold chain limitation that prevented oxytocin distribution at community delivery settings in low-resource contexts, with WHO recommending the heat-stable formulation for prevention of PPH at settings where cold chain cannot be guaranteed.

Tranexamic acid administration within three hours of PPH onset — demonstrated in the WOMAN trial to reduce hemorrhage mortality by nineteen percent at low cost — represents one of the most significant evidence-based advances in PPH management, with global scale-up through inclusion in WHO essential medicines and WHO treatment protocols driving adoption across both hospital and community settings in high-burden countries.

Point-of-care diagnosis of pre-eclampsia risk — using placental growth factor testing to identify women at risk of developing preterm pre-eclampsia for aspirin prophylaxis initiation — enables risk-stratified management that prevents a significant proportion of pre-eclampsia cases through evidence-based intervention.

Do you think universal access to heat-stable uterotonics and tranexamic acid could achieve a fifty percent reduction in PPH mortality in low-income settings within the next decade?

FAQ

What is the leading cause of maternal mortality globally? Postpartum hemorrhage accounts for approximately thirty-five percent of global maternal deaths; other major causes include hypertensive disorders, sepsis, unsafe abortion, and obstructed labor, with the majority of deaths occurring in sub-Saharan Africa and South Asia.

What is tranexamic acid's role in postpartum hemorrhage? Tranexamic acid administered within three hours of PPH diagnosis reduces hemorrhage mortality by approximately nineteen percent in the WOMAN trial; WHO recommends it as first-line treatment for all cases of postpartum hemorrhage.

#MaternalHealth #MaternalMortality #PostpartumHemorrhage #TranexamicAcid #GlobalMaternalHealth #PPHprevention